Li Ma

US Patent:

7314633, Jan 1, 2008

Filed:

Dec 13, 2006

Appl. No.:

11/610171

Inventors:

Jen-Chang Hsia - Irvine CA, US
Li Ma - Statesboro GA, US

Assignee:

SynZyme Technologies LLC - Irvine CA

International Classification:

A61K 9/00

US Classification:

424400

Abstract:

Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives thereof, in a suitable pharmaceutical, cosmetic, and diagnostic formulations are described.

US Patent:

20030045461, Mar 6, 2003

Filed:

Sep 6, 2001

Appl. No.:

09/948505

Inventors:

Jen-Chang Hsia - Irvine CA, US
Li Ma - Statesboro GA, US

International Classification:

A61K038/38
A61K031/44
A61K009/00

US Classification:

514/012000, 514/354000

Abstract:

This invention is directed to the use of novel methods and nitroxide compositions having high redox activity to treat diseases and conditions related to free radicals. The compositions and methods described include pro-drug forms of nitroxide that enhance the therapeutic effect through their ability to penetrate readily into skin cells and remain sequestered within the cells. The formulations and methods described herein result in a significant accumulation of nitroxides in the skin cells, thus achieving a targeted delivery of a therapeutic or diagnostic dose. Applications using the novel compositions and methods described herein include use as improved imaging agents and as improved topical agents for treating conditions of the skin, including aging of the skin, wrinkles caused by sun-exposure, skin cancer, burns, psoriasis and alopecia, among others.

US Patent:

20030078241, Apr 24, 2003

Filed:

Sep 6, 2002

Appl. No.:

10/238020

Inventors:

Jen-Chang Hsia - Irvine CA, US
Li Ma - Statesboro GA, US

International Classification:

A61K031/13
A61K031/655

US Classification:

514/149000, 514/645000

Abstract:

A method of treatment is disclosed whereby a nitroxide compound is administered to a patient in a therapeutically effective amount. The nitroxide compound is comprised of a first portion which comprises a nitrogen atom and an oxygen atom bound directly together and an unpaired electron (.NO), and a second portion which provides a negative charge. The first and second portions are connected directly or indirectly by a linking group positioned between and bound to the first portion and the second portion in a manner such that the negative charge of the second portion stabilizes the .NO of the first portion when the nitroxide is present in the patient. By stabilizing the .NO portion of the molecule the nitroxide is allowed to interact with reactive oxygen species in the patient for a longer period of time and modulate adverse effects of those reactive oxygen species.

US Patent:

20030092764, May 15, 2003

Filed:

Sep 9, 2002

Appl. No.:

10/237558

Inventors:

Jen-Chang Hsia - Irvine CA, US
Li Ma - Statesboro GA, US

International Classification:

A61K031/21
C 07C 2 7/04

US Classification:

514/509000, 558/483000

Abstract:

Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives thereof, in a suitable pharmaceutical, cosmetic, and diagnostic formulations are described.

US Patent:

20030113278, Jun 19, 2003

Filed:

Sep 6, 2002

Appl. No.:

10/237548

Inventors:

Jen-Chang Hsia - Irvine CA, US
Li Ma - Statesboro GA, US

International Classification:

A61K007/42
A61K007/00

US Classification:

424/059000, 424/401000

Abstract:

A method is disclosed whereby a formulation is applied to the skin of a patient which may be a human. The formulation is comprised of a carrier and a compound which has a first lipid solubility and a first aqueous solubility. The compound is allowed to permeate the patient's skin and reach viable cells and react in the presence of enzymes of the cells. The reaction results in a compound which has a second lipid solubility which is substantially less than the first lipid solubility and also obtain a second aqueous solubility which is substantially greater than the first aqueous solubility thereby allowing the compound to permeate to viable cells and remain in contact with those cells. The compound may be a nitroxide which aids in modulating adverse effects of reactive oxygen species.